The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 01, 2025

Filed:

Jul. 29, 2021
Applicants:

The George Washington University, Washington, DC (US);

460medical, Inc., Weston, MA (US);

Inventors:

Marco A. Mercader, Arlington, VA (US);

Narine Sarvazyan, Lambertville, NJ (US);

Terrance J. Ransbury, Chapel Hill, NC (US);

Kenneth C. Armstrong, Cary, NC (US);

Omar Amirana, Weston, MA (US);

Assignees:

The George Washington University, Washington, DC (US);

460Medical, Inc., Weston, MA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61B 5/00 (2006.01); A61B 1/04 (2006.01); A61B 5/02 (2006.01); A61B 18/00 (2006.01); A61B 18/02 (2006.01); A61B 18/12 (2006.01); A61B 90/00 (2016.01); A61B 90/30 (2016.01);
U.S. Cl.
CPC ...
A61B 5/0071 (2013.01); A61B 1/043 (2013.01); A61B 5/0044 (2013.01); A61B 5/0084 (2013.01); A61B 5/02028 (2013.01); A61B 18/00 (2013.01); A61B 90/30 (2016.02); A61B 2018/00351 (2013.01); A61B 18/02 (2013.01); A61B 18/12 (2013.01); A61B 2090/3614 (2016.02); A61B 2576/023 (2013.01);
Abstract

Systems, catheter and methods for treating Atrial Fibrillation (AF) are provided, which are configure to illuminate a heart tissue having a lesion site; obtain a mitochondrial nicotinamide adenine dinucleotide hydrogen (NADH) fluorescence intensity from the illuminated heart tissue along a first line across the lesion site; create a 2-dimensional (2D) map of the depth of the lesion site along the first line based on the NADH fluorescence intensity; and determine a depth of the lesion site at a selected point along the first line from the 2D map, wherein a lower NADH fluorescence intensity corresponds to a greater depth in the lesion site and a higher NADH fluorescence intensity corresponds to an unablated tissue. The process may be repeated to create a 3 dimensional map of the depth of the lesion.


Find Patent Forward Citations

Loading…